Q-omics provides the consensus-scored NLRC4 profile across patient tissues and cancer cell-line models. NLRC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NLRC4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NLRC4 protein abundance shows 21,684 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where NLRC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRC4 survival associations across molecular data types. NLRC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRC4 RNA expression–survival associations across cancer types. High NLRC4 expression shows unfavorable associations in ACC, KIRP, UVM and LGG, but favorable associations in SKCM and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NLRC4 RNA expression.
This table summarizes NLRC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NLRC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRC4 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, THCA and STAD. The KIRC box plot shows higher NLRC4 RNA expression in tumor versus normal tissue (log2 FC = +1.470, t-test p < 0.001).
This table shows molecular features associated with NLRC4 in patient tissues and cancer cell lines. In patient samples, NLRC4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
